2023 World Conference on Lung Cancer (Posters)-EP13.07. Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients

Pdf Summary

The study presented at the World Conference on Lung Cancer in 2023 focused on the efficacy of platinum given after lurbinectedin in sensitive relapsed small cell lung cancer (SCLC) patients. Lurbinectedin is a selective inhibitor of oncogenic transcription that has been approved for the treatment of metastatic SCLC. The study aimed to explore the potential benefits of using platinum-based chemotherapy after treatment with lurbinectedin.<br /><br />The study included 105 patients who received lurbinectedin, and out of these, 60 had a chemotherapy-free interval (CTFI) of at least 90 days. Among those patients, 44 received further systemic therapy after disease progression, with 27 receiving platinum-based chemotherapy. The results of this post-hoc exploratory analysis showed that the baseline characteristics of patients who received or did not receive platinum-based therapy were similar.<br /><br />The efficacy outcomes assessed by the Independent Review Committee (IRC) showed comparable overall response rates (ORR) for lurbinectedin in both patient groups (48.1% vs. 47.1%). However, patients who received further platinum-based therapy had a longer median overall survival (OS) compared to those who did not (15.9 vs. 11.8 months).<br /><br />Furthermore, among the 27 patients who received platinum as immediate line after lurbinectedin, an ORR of 35.3%, a median progression-free survival (PFS) of 3.4 months, and a median OS of 7.2 months were observed while on platinum.<br /><br />The study concluded that platinum rechallenge is a recommended option for second-line platinum-sensitive relapsed SCLC patients. Lurbinectedin is considered a valuable therapeutic option for sensitive SCLC patients as it may extend the platinum-free interval without precluding the use of further platinum-based therapy and improve outcomes.<br /><br />In summary, this study investigated the efficacy of platinum-based chemotherapy after treatment with lurbinectedin in patients with relapsed SCLC. The results suggest that lurbinectedin may improve outcomes and extend the platinum-free interval, making it a valuable treatment option for sensitive SCLC patients.

Asset Subtitle

Jose Manuel Trigo

Meta Tag

Speaker Jose Manuel Trigo

Topic SCLC & Neuroendocrine Tumors: Relapse & Salvage Therapy

Keywords

World Conference on Lung Cancer

platinum

lurbinectedin

small cell lung cancer

SCLC

chemotherapy

metastatic

efficacy

relapsed

therapeutic option